Cell Source, Inc. (CLCS)

Market Cap	7.71K
Revenue (ttm)	n/a
Net Income (ttm)	-5.61M
Shares Out	38.55M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	0.0002
Previous Close	0.0002
Day's Range	0.0002 - 0.0002
52-Week Range	0.0002 - 0.7400
Beta	-150.91
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CLCS

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: CLCS